Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, presents data from the phase Ib KEYNOTE-651 trial (NCT03374254), which assessed pembrolizumab with modified FOLFOX7 or FOLFIRI in patients with metastatic colorectal cancer (mCRC). In two out of five cohorts, patients with microsatellite stable CRC were given first- or second-line pembrolizumab with modified FOLFOX7 or FOLFIRI and the progression-free survival (PFS) was found to be comparable to that of patients not receiving pembrolizumab. Dr Kim additionally discusses the efficacy of certain biomarkers such as PD-L1 levels and the mutational status of KRAS in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the challenges faced when implementing chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of solid tumors. To date, CAR-T cells have shown success only in the treatment of hematological malignancies, however, it remains uncertain whether they will be useful in treating solid tumors. Currently, the main hurdle is finding a suitable antigen in solid tumors for CAR-T cell therapy to bind and carry out their function. Dr. Kim explains that due to the lack of immunogenicity in solid tumors, such as colon and pancreatic cancer, generally they do not tend to harbor the type of cells that respond well to immunotherapy. There are ongoing studies investigating CAR-T therapy alone as well as in combination with immunotherapies for the treatment of solid tumors, however, it is still very much a work in progress and the data is currently premature. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022.